Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders

被引：69

作者：

Li, Peng ^{[1
]}

Zhang, Qiang ^{[1
]}

Robichaud, Albert J. ^{[2
]}

Lee, Taekyu ^{[2
]}

Tomesch, John ^{[1
]}

Yao, Wei ^{[1
]}

Beard, J. David ^{[1
]}

Snyder, Gretchen L. ^{[1
]}

Zhu, Hongwen ^{[1
]}

Peng, Youyi ^{[1
]}

Hendrick, Joseph P. ^{[1
]}

Vanover, Kimberly E. ^{[1
]}

Davis, Robert E. ^{[3
]}

Mates, Sharon ^{[1
]}

Wennogle, Lawrence P. ^{[1
]}

机构：

[1] Intracellular Therapies Inc, New York, NY 10032 USA

[2] Bristol Myers Squibb Res & Dev, Med Chem, Princeton, NJ 08543 USA

[3] 3D Pharmaceut Consultants Inc, San Diego, CA 92130 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2014年 / 57卷 / 06期

关键词：

5-HT2C RECEPTORS; NEUROLEPTICS; ANTAGONISTS; AFFINITIES; RATS;

D O I：

10.1021/jm401958n

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We report the synthesis and structure-activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D-2 receptors. This work has led to the discovery of 44(6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5] pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (ITI-007), which is a potent 5-HT2A antagonist, postsynaptic D-2 antagonist, and inhibitor of serotonin transporter. This multifunctional drug candidate is orally bioavailable and exhibits good antipsychotic efficacy in vivo. Currently, this investigational new drug is under clinical development for the treatment of neuropsychiatric and neurological disorders.

引用

页码：2670 / 2682

页数：13

共 50 条

[31] Discovery of a Tetrahydropyrimidin-2(1H)-one Derivative (TAK-442) as a Potent, Selective, and Orally Active Factor Xa Inhibitor
Fujimoto, Takuya
Imaeda, Yasuhiro
Konishi, Noriko
Hiroe, Katsuhiko
Kawamura, Masaki
Textor, Garret P.
Aertgeerts, Kathleen
Kubo, Keiji
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (09) : 3517 - 3531
[32] Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: Modification of the core skeleton for improved solubility
Ohashi, Tomohiro
Oguro, Yuya
Tanaka, Toshio
Shiokawa, Zenyu
Tanaka, Yuta
Shibata, Sachio
Sato, Yoshihiko
Yamakawa, Hiroko
Hattori, Harumi
Yamamoto, Yukiko
Kondo, Shigeru
Miyamoto, Maki
Nishihara, Mitsuhiro
Ishimura, Yoshimasa
Tojo, Hideaki
Baba, Atsuo
Sasaki, Satoshi
BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (18) : 5507 - 5517
[33] Discovery of SC110237, a highly potent, selective and orally active FLT3 inhibitor for the treatment of acute myeloid leukemia
Kong, Norman
Gao, Daxin
Yang, Heping
Yu, Yajun
CANCER RESEARCH, 2015, 75
[34] Discovery of a 3-Pyridylacetic Acid Derivative (TAK-100) as a Potent, Selective and Orally Active Dipeptidyl Peptidase IV (DPP-4) Inhibitor
Miyamoto, Yasufumi
Banno, Yoshihiro
Yamashita, Tohru
Fujimoto, Tatsuhiko
Oi, Satoru
Moritoh, Yusuke
Asakawa, Tomoko
Kataoka, Osamu
Yashiro, Hiroaki
Takeuchi, Koji
Suzuki, Nobuhiro
Ikedo, Koji
Kosaka, Takuo
Tsubotani, Shigetoshi
Tani, Akiyoshi
Sasaki, Masako
Funami, Miyuki
Amano, Michiko
Yamamoto, Yoshio
Aertgeerts, Kathleen
Yano, Jason
Maezaki, Hironobu
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (03) : 831 - 850
[35] Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer
Meng, Yonggang
Yu, Bin
Huang, He
Peng, Youmei
Li, Ertong
Yao, Yongfang
Song, Chuanjun
Yu, Wenquan
Zhu, Kaikai
Wang, Kai
Yi, Dongxu
Du, Jinfa
Chang, Junbiao
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (02) : 925 - 937
[36] Discovery of novel, orally active, synthetic GPR119 agonists as potential agents for treatment of obesity and associated metabolic disorders
Fyfe, Matthew
Overton, Hilary
White, Jonathan
Jones, Robert
Sorensen, Rikke Veggerby
Reynet, Christine
DIABETES, 2006, 55 : A81 - A81
[37] Discovery of a Potent, Orally Active, and Long-Lasting P2X7 Receptor Antagonist as a Preclinical Candidate for Delaying the Progression of Chronic Kidney Disease
Zhang, Ruijia
Su, Kaiyue
Yang, Letian
Duan, Huaichuan
Tang, Lei
Tang, Minghai
Zhao, Min
Ye, Neng
Cai, Xiaoying
Jiang, Xueqin
Li, Na
Peng, Jing
Zhang, Xinlu
Tang, Lingkai
Qiu, Qiang
Chen, Lijuan
Wu, Wenshuang
Hu, Jianping
Ma, Liang
Ye, Haoyu
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (19) : 17472 - 17496
[38] Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders
Turdi, Huji
Chao, Hannguang
Hangeland, Jon J.
Ahmad, Saleem
Meng, Wei
Brigance, Robert
Zhao, Guohua
Wang, Wei
Moore, Fang
Ye, Xiang-Yang
Mathur, Arvind
Hou, Xiaoping
Kempson, James
Wu, Dauh-Rurng
Li, Yi-Xin
Azzara, Anthony, V
Ma, Zhengping
Chu, Ching-Hsuen
Chen, Luping
Cullen, Mary Jane
Rooney, Suzanne
Harvey, Susan
Kopcho, Lisa
Panemangelor, Reshma
Abell, Lynn
O'Malley, Kevin
Keim, William J.
Dierks, Elizabeth
Chang, Shu
Foster, Kimberly
Apedo, Atsu
Harden, David
Dabros, Marta
Gao, Qi
Pelleymounter, Mary Ann
Whaley, Jean M.
Robl, Jeffrey A.
Cheng, Dong
Lawrence, R. Michael
Devasthale, Pratik
JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (19) : 14773 - 14792
[39] Discovery of EBI-907: A highly potent and orally active B-RafV600E inhibitor for the treatment of melanoma and associated cancers
Lu, Biao
Cao, Hu
Cao, Jingsong
Huang, Song
Hu, Qiyue
Liu, Dong
Shen, Ru
Shen, Xiaodong
Tao, Weikang
Wan, Hong
Wang, Dan
Yan, Yinfa
Yang, Liuqing
Zhang, Jiayin
Zhang, Lei
Zhang, Lianshan
Zhang, Minsheng
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (03) : 819 - 823
[40] Discovery of a Potent and Orally Active Dual GPBAR1/CysLT1R Modulator for the Treatment of Metabolic Fatty Liver Disease
Fiorucci, Stefano
Rapacciuolo, Pasquale
Fiorillo, Bianca
Roselli, Rosalinda
Marchiano, Silvia
Di Giorgio, Cristina
Bordoni, Martina
Bellini, Rachele
Cassiano, Chiara
Conflitti, Paolo
Catalanotti, Bruno
Limongelli, Vittorio
Sepe, Valentina
Biagioli, Michele
Zampella, Angela
FRONTIERS IN PHARMACOLOGY, 2022, 13

← 1 2 3 4 5 →